Andrew E. Clark

Andrew E. Clark

Auto-generated profile, based on publicly available information

Andrew E. Clark

Department of Pathology, University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Microbiology Spectrum
Verified
Journal Article
Closed access
SRSreejana Ray
Sreejana Ray
LFLaurie K. Flemming
Laurie K. Flemming
CSChelsea J. Scudder
Chelsea J. Scudder
MLMelissa A. Ly
Melissa A. Ly
HPHarry S. Porterfield
Harry S. Porterfield
SDSanchita Das
Sanchita Das
Treatment of Achromobacter infections remains challenging due to intrinsic and acquired resistance to commonly used antimicrobial agents and no established clinical breakpoints. We attempted accurate species-level identification and compared the presence of genotypic resistance markers to phenotypic susceptibility patterns in retrospectively collected clinical isolates of Achromobacter spp. Our study concludes that Achromobacter xylosoxidans is the most prevalent species. Commercial matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) systems cannot accurately identify all Achromobacter species due to the limited inclusion of spectra in the databases. Phenotypic antimicrobial susceptibility testing (AST) confirms resistance to the majority of antibiotics tested. Newer agents like delafloxacin, plazomicin, and omadacycline showed little or no activity, while minimum inhibitory concentrations were low for eravacycline. In general, the species other than A. xylosoxidans showed lower MIC 50 and MIC 90 , especially to carbapenems and β-lactamase inhibitor combinations like piperacillin-tazobactam, meropenem-vaborbactam, and imipenem-relebactam. Genotypic analysis confirmed that A. xylosoxidans carries a high number of resistance genes, including multidrug efflux pump AxyXY-OprZ, several class D (OXA-type), and the Class A ß-lactamase bla AXC , while Achromobacter mucicolens has the lowest number of resistance genes and no efflux pumps. This study concludes that there is significant genotypic and phenotypic diversity within the different species of Achromobacter, which are important for the identification of the species and for appropriate antimicrobial therapy. IMPORTANCE: Identification and susceptibility testing of Gram-negative non-fermenting bacteria belonging to the genus Achromobacter is difficult due to the lack of robust databases in commercial identification systems such as matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) and clinical breakpoints for antimicrobial agents. Most clinical laboratories interpret minimum inhibitory concentration data using the “non- Enterobacterales ” breakpoints included in the Clinical and Laboratory Standards Institute (CLSI) M100. These are breakpoints used for a group of organisms for which data is insufficient to provide species-specific interpretation. Our study provides phenotypic data regarding identification and susceptibility testing and correlates this with the genotypic characterization of 109 clinical isolates belonging to Achromobacter spp. This comprehensive study sheds light on the phenotypic and genotypic character of this bacteria, that is of increasing clinical relevance in hospital-acquired infections.

25 May 2022 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
ACAndrew E Clark
Andrew E Clark
ZWZhaohui Wang
Zhaohui Wang
EOEmily Ostman
Emily Ostman
HZHui Zheng
Hui Zheng
HYHuiyu Yao
Huiyu Yao
JSJeffrey SoRelle
Jeffrey SoRelle
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge, and effective tracking requires rapid return of results. Surveillance of variants is typically performed by whole genome sequencing (WGS), which can be financially prohibitive and requires specialized equipment and bioinformatic expertise. Genotyping approaches are rapid methods for monitoring SARS-CoV-2 variants but require continuous adaptation. Fragment analysis may represent an approach for improved SARS-CoV-2 variant detection. Methods: A multiplex fragment analysis approach (CoVarScan) was validated using PCR targeting variants by size and fluorescent color. Eight SARS-CoV-2 mutational hot spots in variants of concern (VOCs) were targeted. Three primer pairs (recurrently deleted region [RDR] 1, RDR2, and RDR3–4) flank RDRs in the S-gene. Three allele-specific primers target recurrent spike receptor binding domain mutants. Lastly, 2 primer pairs target recurrent deletions or insertions in ORF1A and ORF8. Fragments were resolved and analyzed by capillary electrophoresis (ABI 3730XL), and mutational signatures were compared to WGS results. Results: We validated CoVarScan using 3544 clinical respiratory specimens. The assay exhibited 96% sensitivity and 99% specificity compared to WGS. The limit of detection for the core targets (RDR1, RDR2, and ORF1A) was 5 copies/reaction. Variants were identified in 95% of samples with cycle threshold (CT) <30 and 75% of samples with a CT 34 to 35. Assay design was frozen April 2021, but all subsequent VOCs have been detected including Delta (n = 2820), Mu, (n = 6), Lambda (n = 6), and Omicron (n = 309). Genotyping results are available in as little as 4 h. Conclusions: Multiplex fragment analysis is adaptable and rapid and has similar accuracy to WGS to classify SARS-CoV-2 variants.

1 February 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
DHDiana R Hernandez
Diana R Hernandez
DNDuane W Newton
Duane W Newton
NLNathan A Ledeboer
Nathan A Ledeboer
BBBlake Buchan
Blake Buchan
CYCarol Young
Carol Young
DWDonna Marie Wolk
Donna Marie Wolk
Hospitals strive to reduce methicillin-resistantStaphylococcus aureus(MRSA) prevalence via active surveillance of inpatient populations. Rapid and inexpensive screening methods are utilized when molecular methods are not operationally feasible. In this multisite clinical trial, the utility of Bio-Rad's MRSASelectII was evaluated for MRSA identification from remnant nares and wound swabs. The prevalence of MRSA was 11.1% (n= 1,384) from nares samples and 18.1% (n= 842) from wound samples. MRSASelectII had an overall concordance of 95.4% (confidence interval [CI] = 94.5% to 96.2%) compared to a broth-enriched reference standard. Comparisons between results, stratified by examination times, exhibited a nonsignificant trend toward increased positivity at prolonged incubation times. Cefoxitin screening of colonies directly from MRSASelectII was 96.7% (95.8% to 97.3%) concordant compared to testing of colonies following broth enrichment. A comparison of MRSASelectand MRSASelectII revealed no statistical differences; however, the latter exhibited earlier positivity, greater selectivity, and more intense indicator staining, which resulted in facilitated differentiation of positive results. MRSASelectII agar is a simple, rapid, and robust method to routinely screen patients for MRSA colonization without the need for additional testing.

20 January 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
TATomefa Asempa
Tomefa Asempa
ABApril M. Bobenchik
April M. Bobenchik
LBLori Bourassa
Lori Bourassa
ACAndrew E. Clark
Andrew E. Clark
MHMorgan T. Hatch
Morgan T. Hatch
DNDavid Nicolau
David Nicolau

4 November 2025 in ASM Case Reports
Verified
Journal Article
Open access
ACAndrew E. Clark
Andrew E. Clark
LMLakshmi Marimuthu
Lakshmi Marimuthu
ASAnna Sick-Samuels
Anna Sick-Samuels
HMHeba Mostafa
Heba Mostafa
Background: Mycoplasma pneumoniae is a common cause of community-acquired pneumonia among children and young adults. Surveillance within the United States has identified increased levels of M. pneumoniae -mediated respiratory disease following a multi-year period of minimal detection during the COVID-19 pandemic. A wide spectrum of extrapulmonary complications can be associated with M. pneumoniae infections, including dermatological disease. Reactive infectious mucocutaneous eruption (RIME) is a constellation of immune-mediated extrapulmonary manifestations causing ulceration of multiple mucous membranes that occurs in up to 25% M . pneumoniae cases. Case Summary: An adolescent patient presenting with acute hypoxic respiratory failure and an eight-day history of conjunctivitis and oral ulcers tested positive for M. pneumoniae from a nasopharyngeal specimen and was diagnosed with RIME. A retrospective review of increased M. pneumoniae test positivity and hospitalizations at our institution was undertaken, which mirrored national trends. Conclusion: As dedicated M. pneumoniae testing may not be available in all settings, clinicians should consider a diagnosis of RIME for patients presenting with similar para- or post-infectious mucositis, even in the absence of traditional respiratory symptoms. RIME incidence is expected to increase in the setting of a higher prevalence of M. pneumoniae disease. As RIME can be associated with significant morbidity including dehydration and weight loss as well as disease recurrence, proper management of patient symptomatology is essential.

4 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJames Sanders
James Sanders
MMMarguerite Monogue
Marguerite Monogue
DGDavid E. Greenberg
David E. Greenberg
CPChristine A Pybus
Christine A Pybus
ACAndrew E Clark
Andrew E Clark
Cystic fibrosis (CF) patients are often colonized with Pseudomonas aeruginosa (PSA). During treatment, PSA can develop subpopulations exhibiting variable in vitro antimicrobial susceptibility patterns. Heteroresistance may underlie the reported discordant in vitro results and clinical responses to various antimicrobials. Here, we sought to examine the presence and nature of PSA heteroresistance to ceftolozane-tazobactam (C-T) in isolates originating from CF pulmonary exacerbations. Respiratory cultures from 26 adult CF patients were collected. From each sample, 5-10 PSA colonies were selected. Susceptibility testing was conducted via E-test for C-T, ceftazidime-avibactam (CZA), and imipenem-relebactam (I-R). Polyclonal-heteroresistance (PHR) was defined as the presence of different susceptibility profiles among the colonies that originated from a single patient specimen. Population analysis profile (PAPs) were performed to assess the presence of monoclonal-heteroresistance (MHR), defined as ≥ 4 fold change in the C-T MIC from a single colony over 24-48 hours. 246 PSA isolates from 26 adult CF patients were included. The C-T MIC50 and MIC90 were 1/4 and ≥ 256/4 µg/mL, respectively (Figure 1). Sixteen of the 26 patients (62%) demonstrated ≥ 2 fold change in C-T MIC between isolates from the same culture. Of these 16 isolates, the fold change in C-T MIC was >2 fold for 7 isolates (27%) and resulted in a susceptibility interpretation change in 6 of the isolates (23%). Of the 32 isolates that underwent PAP testing, 7 grew on MH plates at 2-fold the C-T MIC concentration. One isolate, PSA 1311, demonstrated growth on PAPs up to 4 fold the MIC (16/4 µg/mL) (Figure 2). Figure 1. Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam MIC distributions against PSA isolates from 26 adult CF patients Figure 2. Monoclonal heteroresistance to C-T (PSA 1311 [C-T MIC 1/4 µg/mL] PAPs at 2, 4, 6, and 8-fold the C-T MIC). Susceptibilities to C-T and CZA were similar across our CF PSA isolates. Comparatively, I-R retained better in vitro potency. C-T PHR exists among PSA isolates in the majority of our CF patients. Approximately 25% of these PHR isolates resulted in susceptibility interpretation changes supporting concerns surrounding the utility of traditional susceptibility testing methodology for CF isolates. These data suggest MHR also exists, albeit rare in this small subset. Additional data are needed to better understand these results in clinical context. David E. Greenberg, MD, Shionogi (Grant/Research Support)Solenic Medical (Shareholder)